WO2023223097 - ANTIBODY DRUG CONJUGATES
National phase entry:
Publication Number
WO/2023/223097
Publication Date
23.11.2023
International Application No.
PCT/IB2023/000277
International Filing Date
19.05.2023
Title **
[English]
ANTIBODY DRUG CONJUGATES
[French]
CONJUGUÉS ANTICORPS-MÉDICAMENTS
Applicants **
NOVARTIS AG
Inventors
BURGER, Matthew, T.
CHEN, Zhuoliang
D'ALESSIO, Joseph, Anthony
HOLLINGWORTH, Gregory, John
KLINTER, Claudia, Judith
LANGLOIS, Jean-Baptiste
MCNEILL, Eric
MUNDT, Cornelia, Anne
NAKAJIMA, Katsumasa
MADÖRIN, Katharina
YU, Bing
ZHANG, Qiang
Priority Data
63/344,455
20.05.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 19923 | |
| EPO | Filing, Examination, Granting | 316041 | |
| Japan | Filing, Examination, Granting | 5669 | |
| South Korea | Filing, Examination, Granting | 16503 | |
| USA | Filing, Examination, Granting | 60540 |
Total:
418,676
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to antibody-drug conjugates (ADCs) comprising an antibody or an antigen-binding fragment thereof covalently linked to two pharmaceutically active drugs through a dual linker. Linker-drug conjugates comprising the dual linker and the pharmaceutically active drugs are also disclosed. Such linkers are a convenient way of delivering two (e.g. two different or two of the same) drugs connected to a single antibody. Such linkers may be particularly useful in improving the solubility of antibody drug conjugates (ADCs) which comprise one or more hydrophobic drug compounds.[French]
La présente invention concerne des conjugués anticorps-médicaments (ADC) comprenant un anticorps ou un fragment de liaison à l'antigène de celui-ci lié de manière covalente à deux médicaments pharmaceutiquement actifs par l'intermédiaire d'un lieur double. L'invention concerne également des conjugués lieur-médicaments comprenant le lieur double et les médicaments pharmaceutiquement actifs. De tels lieurs sont une manière pratique de fournir deux (par exemple deux différents ou deux identiques) médicaments associés à un seul anticorps. De tels lieurs peuvent être particulièrement utiles pour améliorer la solubilité de conjugués anticorps-médicaments (ADC) qui comprennent un ou plusieurs composés médicamenteux hydrophobes.